Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
14.41B
Market cap14.41B
Price-Earnings ratio
23.76
Price-Earnings ratio23.76
Dividend yield
Dividend yield
Average volume
602.88K
Average volume602.88K
High today
$234.59
High today$234.59
Low today
$222.70
Low today$222.70
Open price
$223.49
Open price$223.49
Volume
812.45K
Volume812.45K
52 Week high
$250.74
52 Week high$250.74
52 Week low
$160.86
52 Week low$160.86

Stock Snapshot

With a market cap of 14.41B, Ascendis Pharma A/S(ASND) trades at $233.56. The stock has a price-to-earnings ratio of 23.76.

On 2026-06-16, Ascendis Pharma A/S(ASND) stock traded between a low of $222.70 and a high of $234.59. Shares are currently priced at $233.56, which is +4.9% above the low and -0.4% below the high.

Ascendis Pharma A/S(ASND) shares are trading with a volume of 812.45K, against a daily average of 602.88K.

In the last year, Ascendis Pharma A/S(ASND) shares hit a 52-week high of $250.74 and a 52-week low of $160.86.

In the last year, Ascendis Pharma A/S(ASND) shares hit a 52-week high of $250.74 and a 52-week low of $160.86.

ASND News

Investing.com 2d
Oppenheimer reiterates Ascendis Pharma stock rating on drug data - Investing.com

...

Oppenheimer reiterates Ascendis Pharma stock rating on drug data - Investing.com
TipRanks 2d
Ascendis Pharma Posts Strong 3.5-Year Phase 3 Data for TransCon PTH in Hypoparathyroidism

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 2d
Ascendis Pharma completes Phase 3 PaTHway Trial

Ascendis Pharma (ASND) announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH demonstrated sustaine...

Analyst ratings

100%

of 19 ratings
Buy
100%
Hold
0%
Sell
0%

More ASND News

TipRanks 5d
Ascendis Pharma announces five-year data from PaTH Forward Trial

Ascendis Pharma (ASND) announced five-year data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH demonstrated sustained ef...

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.